Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures.
Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B, William D, Gieldon L, Maurer J, Spöttl G, Rank P, Knösel T, Orth M, Ziegler CG, Aristizabal Prada ET, Rubinstein G, Fassnacht M, Spitzweg C, Grossman AB, Pacak K, Beuschlein F, Bornstein SR, Eisenhofer G, Auernhammer CJ, Reincke M, Nölting S. Fankhauser M, et al. Among authors: lauseker m. Endocrinology. 2019 Nov 1;160(11):2600-2617. doi: 10.1210/en.2019-00410. Endocrinology. 2019. PMID: 31322702 Free PMC article.
Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.
Nölting S, Giubellino A, Tayem Y, Young K, Lauseker M, Bullova P, Schovanek J, Anver M, Fliedner S, Korbonits M, Göke B, Vlotides G, Grossman A, Pacak K. Nölting S, et al. Among authors: lauseker m. Endocrinology. 2014 Jul;155(7):2377-90. doi: 10.1210/en.2014-1027. Epub 2014 Apr 24. Endocrinology. 2014. PMID: 24762141 Free PMC article.
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group. Nölting S, et al. Among authors: lauseker m. PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. eCollection 2017. PLoS One. 2017. PMID: 28800359 Free PMC article.
GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Aristizabal Prada ET, Weis C, Orth M, Lauseker M, Spöttl G, Maurer J, Grabowski P, Grossman A, Auernhammer CJ, Nölting S. Aristizabal Prada ET, et al. Among authors: lauseker m. Neuroendocrinology. 2018;106(4):335-351. doi: 10.1159/000481887. Epub 2017 Oct 2. Neuroendocrinology. 2018. PMID: 28968593 Free article.
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.
Aristizabal Prada ET, Spöttl G, Maurer J, Lauseker M, Koziolek EJ, Schrader J, Grossman A, Pacak K, Beuschlein F, Auernhammer CJ, Nölting S. Aristizabal Prada ET, et al. Among authors: lauseker m. Endocr Relat Cancer. 2018 Oct;25(10):893-908. doi: 10.1530/ERC-18-0159. Epub 2018 Jun 12. Endocr Relat Cancer. 2018. PMID: 29895527 Free PMC article.
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
Wang K, Schütze I, Gulde S, Bechmann N, Richter S, Helm J, Lauseker M, Maurer J, Reul A, Spoettl G, Klink B, William D, Knösel T, Friemel J, Bihl M, Weber A, Fankhauser M, Schober L, Vetter D, Broglie Däppen M, Ziegler CG, Ullrich M, Pietzsch J, Bornstein SR, Lottspeich C, Kroiss M, Fassnacht M, Wenter VUJ, Ladurner R, Hantel C, Reincke M, Eisenhofer G, Grossman AB, Pacak K, Beuschlein F, Auernhammer CJ, Pellegata NS, Nölting S. Wang K, et al. Among authors: lauseker m. Endocr Relat Cancer. 2022 May 9;29(6):285-306. doi: 10.1530/ERC-21-0355. Endocr Relat Cancer. 2022. PMID: 35324454
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R; German CML Study Group. Saussele S, et al. Among authors: lauseker m. Blood. 2010 Mar 11;115(10):1880-5. doi: 10.1182/blood-2009-08-237115. Epub 2009 Nov 18. Blood. 2010. PMID: 19965667 Free article. Clinical Trial.
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A; SAKK; German CML Study Group. Hanfstein B, et al. Among authors: lauseker m. Leukemia. 2012 Sep;26(9):2096-102. doi: 10.1038/leu.2012.85. Epub 2012 Mar 26. Leukemia. 2012. PMID: 22446502 Clinical Trial.
82 results